Beth Y. Karlan

Oncology

1010 Veteran Ave
Los Angeles, CA 90024

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 312 publications

A Multilevel Intervention to Identify Individuals for Genetic Testing and Treatment: The IGNITE-TX Pilot Randomized Clinical Trial.

A Multilevel Intervention to Identify Individuals for Genetic Testing and Treatment: The IGNITE-TX Pilot Randomized Clinical Trial.

Journal: JAMA network open

Published: August 27, 2026

Deformability screening identifies NUDT5 as a mediator of cellular mechanobiology.

Deformability screening identifies NUDT5 as a mediator of cellular mechanobiology.

Journal: bioRxiv : the preprint server for biology

Published: July 29, 2026

Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer.

Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer.

Journal: Gynecologic oncology reports

Published: July 03, 2026

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.

Journal: Gynecologic oncology

Published: June 14, 2026

En-Do's and En-Don'ts: Navigating the rapidly evolving clinical landscape in endometrial cancer.

En-Do's and En-Don'ts: Navigating the rapidly evolving clinical landscape in endometrial cancer.

Journal: Gynecologic oncology

Published: June 06, 2026

Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy.

Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy.

Journal: Gynecologic oncology

Published: April 01, 2026

Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related markers.

Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related markers.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 31, 2026

Genome-wide classification of tumor-derived reads from bulk long-read sequencing.

Genome-wide classification of tumor-derived reads from bulk long-read sequencing.

Journal: bioRxiv : the preprint server for biology

Published: March 18, 2026

Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2.

Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 28, 2026

Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

Journal: Gynecologic oncology

Published: February 23, 2026

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 11, 2026

Molecular and spatial differences in the tumor microenvironment of high-grade serous ovarian cancers with short versus long-term survival.

Molecular and spatial differences in the tumor microenvironment of high-grade serous ovarian cancers with short versus long-term survival.

Journal: Gynecologic oncology

Published: January 05, 2026

Showing 1-12 of 312

Last Updated: 09/26/2026